BioNTech has said that it expected its Covid-19 vaccine, jointly developed with Pfizer, to be available to 12 to 15-year-olds in Europe from June.

BioNTech CEO Ugur Sahin told Der Spiegel weekly that it was "in the final stretches" of preparing its submission for European regulatory approval.

The evaluation of the trial data "takes four to six weeks on average", he added.

Vaccinating children is seen as a crucial next step toward herd immunity and ending the pandemic.

The prospect of getting older children inoculated before the next school year starts would also relieve the strain on parents who are juggling the demands of homeschooling while keeping up with jobs.

"It's very important to enable children a return to their normal school lives and allow them to meet with family and friends," Sahin told Spiegel.

BioNTech/Pfizer already applied for emergency US authorisation of their jab for 12 to 15-year-olds earlier this month.

Mr Sahin expects to submit a similar request to the European Medicines Agency (EMA) next Wednesday, he told Spiegel.

Latest coronavirus stories

The move comes after BioNTech and Pfizer in late March announced that phase 3 clinical trials of their vaccine for children aged 12-15 showed it was 100% effective in warding off the disease.

Both companies are also racing to get the jab approved for younger children, from six months upwards.

"In July, the first results for five to 12-year-olds could be available, and those for younger children in September," he said.

Ongoing trials so far are "very encouraging", Mr Sahin said, suggesting that "children are very well protected by the vaccine".

The BioNTech/Pfizer shot is based on novel mRNA technology and was the first Covid-19 jab to be approved in the West late last year.

Moderna to double vaccine production to 3 billion shots in 2022

Moderna has said it is boosting manufacturing capacity for its Covid-19 vaccine and expects to make up to 3 billion doses in 2022, more than twice its previous forecast.

It also said it is increasing its expectations for 2021 vaccine production to between 800 million and 1bn shots, raising the bottom of its range from 700m.

The final number of inoculations will depend on how many are lower-dose formulations for boosters and immunisations for children.

Moderna shots currently deploy 100 micrograms of vaccine substance but some future shots may use only 50 micrograms.

"As we look forward to next year, we just see so much need for primary vaccine, we are hearing it all over the world, and also boosters," Moderna President Stephen Hoge said in an interview.

"So depending upon... how much the ordering that happens is third doses or paediatric doses at 50 micrograms, we could see up to 3 billion doses," he added.



Moderna had previously said it expected to make 1.4bn shots in 2022.

Moderna also said new data suggests its shots can be stored safely for up to three months at refrigerator temperatures, making it easier to get them to hard to reach areas that may not have access to freezers.

"That might be a breakthrough that really matters in 2022 in Africa and across lower and middle income countries," Mr Hoge said.

Wealthy governments have been trying to stock up on COVID-19 shots from Moderna and Pfizer Inc/BioNTech SE after safety concerns and production problems temporarily sidelined vaccines from AstraZeneca Plc and Johnson and Johnson.

But even as rich countries speed up their vaccine rollouts, other parts of the world are facing sharp upticks in cases and struggling to acquire needed shots.

India has recorded more than 300,000 cases each day and more than 2,000 deaths in the past week. Fewer than 10% of its more than 1.3bn citizens have received one dose and only around 20m are fully inoculated against the virus.

Moderna expects to double output at a drug substance plant in Switzerland run by Lonza Group AG and boost production in a Spain-based facility owned by Laboratorios Farmaceuticos ROVI SA more than two-fold. US plants will also raise output by more than 50%.

Moderna's two-dose vaccine uses messenger-RNA technology that programs cells to build immunity to the novel coronavirus.

The US drug maker said it would begin making investments this year and that production boosts would start in late 2021 and carry into early 2022.

Moderna said it is in advanced talks for additional deals with other manufacturers to help make its shots. Moderna earlier this month announced shot production deals with Sanofi SA and Catalent Inc.

The company would need regulatory sign-off to start shipping vaccine at the higher, refrigerator-level temperatures.

So far, Johnson & Johnson and AstraZeneca have been the only major global drug makers with authorized Covid-19 shots that can be stored without a freezer.

Both companies have faced production problems and reports of severe side effects that have slowed uptake of their vaccines.

Guest

Pfizer-BioNTech eye Covid vaccine for 12-15 year olds from June in EU

58 views
0

BioNTech has said that it expected its Covid-19 vaccine, jointly developed with Pfizer, to be available to 12 to 15-year-olds in Europe from June.

BioNTech CEO Ugur Sahin told Der Spiegel weekly that it was "in the final stretches" of preparing its submission for European regulatory approval.

The evaluation of the trial data "takes four to six weeks on average", he added.

Vaccinating children is seen as a crucial next step toward herd immunity and ending the pandemic.

The prospect of getting older children inoculated before the next school year starts would also relieve the strain on parents who are juggling the demands of homeschooling while keeping up with jobs.

"It's very important to enable children a return to their normal school lives and allow them to meet with family and friends," Sahin told Spiegel.

BioNTech/Pfizer already applied for emergency US authorisation of their jab for 12 to 15-year-olds earlier this month.

Mr Sahin expects to submit a similar request to the European Medicines Agency (EMA) next Wednesday, he told Spiegel.

Latest coronavirus stories

The move comes after BioNTech and Pfizer in late March announced that phase 3 clinical trials of their vaccine for children aged 12-15 showed it was 100% effective in warding off the disease.

Both companies are also racing to get the jab approved for younger children, from six months upwards.

"In July, the first results for five to 12-year-olds could be available, and those for younger children in September," he said.

Ongoing trials so far are "very encouraging", Mr Sahin said, suggesting that "children are very well protected by the vaccine".

The BioNTech/Pfizer shot is based on novel mRNA technology and was the first Covid-19 jab to be approved in the West late last year.

Moderna to double vaccine production to 3 billion shots in 2022

Moderna has said it is boosting manufacturing capacity for its Covid-19 vaccine and expects to make up to 3 billion doses in 2022, more than twice its previous forecast.

It also said it is increasing its expectations for 2021 vaccine production to between 800 million and 1bn shots, raising the bottom of its range from 700m.

The final number of inoculations will depend on how many are lower-dose formulations for boosters and immunisations for children.

Moderna shots currently deploy 100 micrograms of vaccine substance but some future shots may use only 50 micrograms.

"As we look forward to next year, we just see so much need for primary vaccine, we are hearing it all over the world, and also boosters," Moderna President Stephen Hoge said in an interview.

"So depending upon... how much the ordering that happens is third doses or paediatric doses at 50 micrograms, we could see up to 3 billion doses," he added.



Moderna had previously said it expected to make 1.4bn shots in 2022.

Moderna also said new data suggests its shots can be stored safely for up to three months at refrigerator temperatures, making it easier to get them to hard to reach areas that may not have access to freezers.

"That might be a breakthrough that really matters in 2022 in Africa and across lower and middle income countries," Mr Hoge said.

Wealthy governments have been trying to stock up on COVID-19 shots from Moderna and Pfizer Inc/BioNTech SE after safety concerns and production problems temporarily sidelined vaccines from AstraZeneca Plc and Johnson and Johnson.

But even as rich countries speed up their vaccine rollouts, other parts of the world are facing sharp upticks in cases and struggling to acquire needed shots.

India has recorded more than 300,000 cases each day and more than 2,000 deaths in the past week. Fewer than 10% of its more than 1.3bn citizens have received one dose and only around 20m are fully inoculated against the virus.

Moderna expects to double output at a drug substance plant in Switzerland run by Lonza Group AG and boost production in a Spain-based facility owned by Laboratorios Farmaceuticos ROVI SA more than two-fold. US plants will also raise output by more than 50%.

Moderna's two-dose vaccine uses messenger-RNA technology that programs cells to build immunity to the novel coronavirus.

The US drug maker said it would begin making investments this year and that production boosts would start in late 2021 and carry into early 2022.

Moderna said it is in advanced talks for additional deals with other manufacturers to help make its shots. Moderna earlier this month announced shot production deals with Sanofi SA and Catalent Inc.

The company would need regulatory sign-off to start shipping vaccine at the higher, refrigerator-level temperatures.

So far, Johnson & Johnson and AstraZeneca have been the only major global drug makers with authorized Covid-19 shots that can be stored without a freezer.

Both companies have faced production problems and reports of severe side effects that have slowed uptake of their vaccines.

Uploaded to β€” 2 weeks ago

Edit or resize any image by clicking the image preview
Edit any image by touching the image preview
You can add more images from your computer or add image URLs.
You can add more images from your device, take a picture or add image URLs.
Uploading 0 image (0% complete)
The queue is being uploaded, it should take just a few seconds to complete.
Upload complete
Uploaded content added to . You can create a new album with the content just uploaded.
Uploaded content added to .
You can create a new album with the content just uploaded. You must create an account or sign in to save this content into your account.
No image have been uploaded
Some errors have occured and the system couldn't process your request.
    or cancelcancel remaining
    Note: Some images couldn't be uploaded. learn more
    Check the error report for more information.
    JPG PNG BMP GIF WEBP 7.5 MB